



ISSN: 2348-6295

Journal of Pharma Creations (JPC)

JPC | Vol.10 | Issue 4 | Oct - Dec -2023

www.pharmacreations.com

DOI : <https://doi.org/10.61096/jpc.v10.iss4.2023.234-238>



Review

A review on FanconiAnemia

S. Nagarajan*

Assistant Professor, Department of Pharmacy Practice, S. A. Raja Pharmacy College, Raja Nagar, Vadakangulam, Tirunelveli, Tamil Nadu, India.

*Author for Correspondence: S.Nagarajan, M. Pharm
Email:nagapharmacy88@gmail.com

	Abstract
Published on:05Oct2023	<p>FanconiAnemia (FA) is a rare, inherited disorder primarily characterized by bone marrow failure, leading to reduced blood cell production and consequent anemia, leukopenia, and thrombocytopenia. This condition is also associated with congenital abnormalities, increased cancer risk (especially leukemia and tumors in the head, neck, and reproductive organs), and endocrine problems. FA is a genetically heterogeneous disorder caused by mutations in over 20 identified genes and is typically transmitted in an autosomal recessive pattern. Diagnosis methods include blood tests and chromosome breakage tests. Management of FA is multifaceted, encompassing blood transfusions, bone marrow transplants, hormone therapy, surgery, and preventive monitoring for associated health risks. Treatment responses and prognosis vary among individuals, with continual research and medical advancements improving the outlook for those with FA. For up-to-date and personalized medical advice, consultation with healthcare professionals is essential.</p>
Published by: DrSriram Publications	
2023 All rights reserved.  Creative Commons Attribution 4.0 International License.	
Keywords: FanconiAnemia (FA), bone marrow failure, congenital abnormalities, increased cancer risk, genetic mutations.	

INTRODUCITON

FanconiAnemia (FA) is a rare and serious inherited genetic disorder characterized primarily by bone marrow failure, which leads to diminished production of all types of blood cells⁽¹⁾. Affected individuals may have lower-than-normal levels of red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia), resulting in a range of symptoms including fatigue, increased susceptibility to infections, and excessive bleeding⁽²⁾.

Beyond its impact on blood cell production, FA is also associated with various congenital abnormalities and an increased risk of cancer, particularly leukemia and solid tumors of the head, neck, and reproductive system. Individuals with FA might exhibit physical abnormalities such as short stature, abnormalities in the structure of the thumbs and forearms, kidney problems, and heart defects. Additionally, they might experience endocrine issues including diabetes and hypothyroidism⁽³⁾.

Genetically, FanconiAnemia is typically transmitted in an autosomal recessive manner, meaning that a person must inherit two defective copies of the gene, one from each parent, to develop the disorder. More than

20 genes have been identified whose mutations can cause FA, making it a genetically heterogeneous disorder. The disease can be diagnosed through various means including blood tests and chromosome breakage tests, which analyze the chromosomal response to specific chemicals⁽⁴⁾.

Etiology

Genetic Mutations

FA is characterized by mutations in the FANCG group of genes, with FANCA, FANCC, and FANCG mutations being the most common. These genes are crucial for the repair of DNA damage within cells, helping maintain genomic stability. The mutations lead to defective DNA repair mechanisms, making cells more susceptible to damage and apoptosis, especially in the bone marrow. This defect results in the characteristic bone marrow failure observed in individuals with FA.

Inheritance Pattern

The majority of FA cases are transmitted through an autosomal recessive pattern. In autosomal recessive inheritance, an individual must inherit two mutated copies of the responsible gene, one from each parent, to manifest the disorder. Parents who are carriers (owning one mutated and one normal gene) do not typically show signs of the disease but have a 25% chance of having a child with FA in each pregnancy. Rarely, FA can also be inherited in an X-linked or autosomal dominant manner.

Environmental Factors

While the primary etiological factor of FA is genetic mutations, environmental factors can exacerbate the condition. Individuals with FA are highly sensitive to oxidative stress and DNA-damaging agents found in the environment, like certain chemicals and radiation. These environmental stressors can further compromise DNA repair and contribute to the progression of bone marrow failure and cancer development in FA patients.

Clinical Manifestations

FanconiAnemia (FA) is marked by a series of clinical manifestations that span across various body systems, primarily affecting the bone marrow but also presenting with congenital abnormalities, increased cancer risks, and endocrine dysfunctions.

Hematologic Manifestations

- **Bone Marrow Failure:** The hallmark manifestation of FA is progressive bone marrow failure, leading to aplastic anemia. This results in the insufficient production of red blood cells (causing anemia), white blood cells (leading to leukopenia), and platelets (resulting in thrombocytopenia).
- **Anemia:** Patients often experience fatigue, weakness, and pallor due to reduced red blood cell count.
- **Leukopenia:** Low white blood cell count increases susceptibility to infections.
- **Thrombocytopenia:** A decreased platelet count may lead to easy bruising and excessive bleeding.

Physical Abnormalities

- **Skeletal Abnormalities:** These may include short stature, abnormal thumb and/or radial development, and other skeletal malformations.
- **Organ Malformations:** Abnormalities in the kidneys, heart, gastrointestinal system, and reproductive organs can occur.
- **Skin Pigmentation:** Patients may exhibit café-au-lait spots, hypopigmentation, or hyperpigmentation.

Oncologic Manifestations

- **Increased Cancer Risk:** Individuals with FA have a higher risk of developing acute myeloid leukemia (AML) and squamous cell carcinomas, particularly in the head, neck, and reproductive organs.
- **Leukemia:** FA patients have a significant predisposition to developing leukemia, often at a young age.

Endocrine Manifestations

- **Endocrine Dysfunctions:** Various issues can arise, including growth hormone deficiency, hypothyroidism, and diabetes, impacting growth and overall metabolism.

Others

- **Neurological Issues:** Though less common, some individuals with FA may experience developmental delays and intellectual disabilities.

Symptoms

FanconiAnemia (FA) presents with a wide variety of symptoms due to its impact on multiple body systems. Symptoms can vary significantly from one individual to another, and not every person with FA will experience all of these symptoms.

Hematologic Symptoms

1. Fatigue and Weakness: Resulting from anemia due to reduced red blood cell count.
2. Frequent Infections: Due to leukopenia, or low levels of white blood cells.
3. Easy Bruising and Bleeding: Caused by thrombocytopenia, or low platelet count.

Physical and Developmental Symptoms

1. Short Stature: Growth retardation is common.
2. Skin Pigmentation: Presence of café-au-lait spots, hypopigmentation, or hyperpigmentation.
3. Abnormal Thumb and/or Forearm Development: Thumb may be absent, duplicated, or malformed; radius may also be underdeveloped or absent.
4. Structural Abnormalities of the Kidneys, Heart, and Other Organs: Including horseshoe kidney, septal defects in the heart, etc.
5. Eye and Ear Anomalies: Such as microphthalmia (abnormally small eyes) or hearing loss.

Reproductive Symptoms

1. Females: Females with FA may have reduced fertility, and they often experience early menopause.
2. Males: Many males with FA are infertile, often due to abnormalities in the reproductive organs.

Cancer-Related Symptoms

1. Unexplained Weight Loss and Fatigue: Often associated with leukemia or other cancers.
2. Lumps, Sores, or Discolorations That Don't Heal: Especially in areas like the mouth, throat, or genitals, which might indicate squamous cell carcinoma.

Others

1. Learning Disabilities and Developmental Delays: Though not as common, some individuals with FA might exhibit intellectual challenges and delays in developmental milestones.

Important Note

Given the variability and range of symptoms, and the potential for severe outcomes like bone marrow failure and cancer, individuals suspected of having FanconiAnemia should receive a comprehensive evaluation and ongoing monitoring by healthcare professionals. Early diagnosis and intervention are crucial for managing the disease effectively and improving the quality of life for those affected. For the most accurate diagnosis and treatment, always consult with qualified and licensed healthcare providers.

Diagnosis

The diagnosis of FanconiAnemia (FA) is typically a multistep process that involves clinical assessment, laboratory testing, and genetic analysis. Since FA can manifest with a wide range of symptoms, the diagnosis is often complex and requires a thorough evaluation.

Clinical Assessment

1. Medical History: A detailed history of the patient, including any symptoms, family history of FA or other genetic disorders, and any related medical conditions.
2. Physical Examination: Physicians may look for characteristic physical abnormalities associated with FA, such as skin pigmentation changes, thumb and forearm deformities, and short stature.

Laboratory Testing

1. Complete Blood Count (CBC): A CBC is crucial for assessing the levels of red blood cells, white blood cells, and platelets in the blood. Individuals with FA often show decreased levels of these cells.
2. Bone Marrow Aspiration and Biopsy: These procedures involve taking samples of bone marrow for examination. They help evaluate the status of the bone marrow and the presence of any abnormalities.
3. Chromosome Breakage Test: This is a definitive test for FA, where cells (usually blood or skin cells) are cultured and treated with DNA-damaging agents like diepoxybutane (DEB) or mitomycin C (MMC). Cells from individuals with FA will show increased chromosomal breakage and rearrangements compared to normal cells.

Genetic Analysis

1. Molecular Genetic Testing: This involves the identification of mutations in the known FA genes. More than 20 genes associated with FA have been identified, and mutations in these genes can confirm the diagnosis.
2. Carrier Testing: For families with a history of FA, carrier testing can be conducted to identify individuals who carry one copy of the mutated gene. This is important for family planning and understanding the risk of having children with FA.

Prenatal Diagnosis

1. Amniocentesis and Chorionic Villus Sampling (CVS): For families at risk, these prenatal testing methods can diagnose FA in a fetus. Cells from the amniotic fluid or placenta are analyzed for the presence of FA gene mutations.

Management and Treatment

Managing and treating Fanconi Anemia (FA) requires a multifaceted approach due to the diverse manifestations and complications associated with the disorder. The following outlines general management and treatment strategies for FA:

Supportive Care

1. **Blood Transfusions:** Regular transfusions might be necessary to manage anemia and thrombocytopenia. However, this is usually a temporary measure and not a long-term solution.
2. **Growth Factors:** Medications like erythropoietin and G-CSF can stimulate the bone marrow to produce more blood cells.

Bone Marrow Failure Management

1. **Androgens:** These are male hormones that can stimulate the bone marrow to produce blood cells. They can have side effects and are not effective in all patients.
2. **Bone Marrow (Stem Cell) Transplant:** This is the primary treatment for bone marrow failure in FA. A successful transplant can provide a continuous source of healthy blood cells. The process involves using chemotherapy and/or radiation to destroy the diseased bone marrow, followed by infusion of healthy stem cells from a donor.

Cancer Prevention and Treatment

1. **Regular Surveillance:** Due to increased cancer risk, patients need regular screenings for early detection of malignancies.
2. **Chemotherapy and Radiation:** Standard cancer treatments might be effective, though FA patients may have increased sensitivity to these therapies, necessitating dose adjustments.
3. **Surgery:** For solid tumors, surgical removal may be an option.

Treatment of Congenital Anomalies

1. **Surgical Intervention:** Physical abnormalities, especially in the thumbs, arms, and organs, may require surgical correction or reconstruction.
2. **Hormonal Therapy:** For endocrine issues, hormone replacement or other therapies may be necessary.

Genetic Counseling and Psychosocial Support

1. **Counseling:** Since FA is hereditary, genetic counseling is crucial for affected individuals and their families to understand the risk of transmission to offspring.
2. **Psychosocial Support:** Living with FA can be challenging, and patients and their families may benefit from psychological and social support.

Clinical Trials and Emerging Therapies

1. **Participation in Clinical Trials:** New treatments for FA are under investigation, and patients might consider participating in clinical trials after discussing with healthcare providers.
2. **Gene Therapy:** Research is ongoing, and experimental treatments that target the genetic basis of FA are being developed.

Prognosis

The prognosis for individuals with Fanconi Anemia (FA) can vary significantly, depending on various factors including the severity of symptoms, the presence and nature of complications, and the effectiveness of treatments applied.

Factors Influencing Prognosis

1. **Severity of Bone Marrow Failure:** The degree of bone marrow failure and the body's response to treatments like bone marrow transplantation play crucial roles in determining the patient's outlook.
2. **Presence of Physical Abnormalities:** Congenital anomalies and physical abnormalities can influence the quality of life and might require surgical interventions, which also carry risks and potential complications.
3. **Development of Cancers:** Individuals with FA have a higher risk of developing cancers, particularly leukemia and solid tumors of the head, neck, and reproductive organs. Early detection and effective treatment of cancers are critical for improving the prognosis.
4. **Response to Treatment:** The body's response to various treatments, including blood transfusions, hormone therapy, and particularly stem cell transplantation, can significantly influence the outcome.
5. **General Health and Comorbidities:** Overall health status and the presence of other health conditions can affect the prognosis and life expectancy of individuals with FA.

General Prognostic Outlook

- With advances in treatment and management, including successful bone marrow transplants, many individuals with FA can live into adulthood. However, the risk of developing cancers remains a significant concern, necessitating continuous monitoring and preventive care.

- The life expectancy of individuals with FA has been increasing with improved medical care and therapies. However, it is still generally lower than that of the general population due to the disorder's complications and associated risks.
- The quality of life for individuals with FA can be affected by the disorder's physical and emotional burdens, highlighting the importance of psychosocial support and counselling.

CONCLUSION

The prognosis for FA is complex and multifactorial. While treatment advances have improved life expectancy and quality of life for many individuals with FA, living with the disorder requires diligent medical care, regular monitoring for complications, and support for the emotional and social challenges that may arise. For the most precise and personalized prognostic information, individuals should consult with healthcare professionals who are familiar with their unique health profile and medical history.

REFERENCES

1. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. *N Engl J Med.* 2010;362(20):1909-19. doi: [10.1056/NEJMra0809889](https://doi.org/10.1056/NEJMra0809889), PMID [20484397](https://pubmed.ncbi.nlm.nih.gov/20484397/).
2. Auerbach AD. Fanconianemia diagnosis and the diepoxybutane (DEB) test. *ExpHematol.* 1993;21(6):731-3.
3. van der Lelij P, Oostra AB, Rooimans MA, Joenje H, de Winter JP. Diagnostic overlap between fanconianemia and the Cohesinopathies: Robertssyndrome and Warsaw Breakage Syndrome. *Anemia.* 2010;2010:565268. doi: [10.1155/2010/565268](https://doi.org/10.1155/2010/565268), PMID [21490908](https://pubmed.ncbi.nlm.nih.gov/21490908/).
4. FanconianemiaSJ. *Hematol Am SocHematolEduc Program.* 2011;2011:492-7.
5. Giampietro PF, Adler-Brecher B, Verlander PC, Pavlakis SG, Davis JG, Auerbach AD. The need for more accurate and timely diagnosis in fanconianemia: a report from the International fanconianemia Registry. *Pediatrics.* 1993;91(6):1116-20. View this article via: doi: [10.1542/peds.91.6.1116](https://doi.org/10.1542/peds.91.6.1116), PMID [8502512](https://pubmed.ncbi.nlm.nih.gov/8502512/), Google Scholar.
6. Giri N, Batista DL, Alter BP, Stratakis CA. Endocrine abnormalities in patients with fanconianemia. *J ClinEndocrinolMetab.* 2007;92(7):2624-31. View this article via: [PubMed CrossRef Google Scholar](https://pubmed.ncbi.nlm.nih.gov/18454466/)
7. Elder DA, D'Alessio DA, Eyal O, Mueller R, Smith FO, Kansra AR, et al. Abnormalities in glucose tolerance are common in children with fanconianemia and associated with impaired insulin secretion. *Pediatr Blood Cancer.* 2008;51(2):256-60. doi: [10.1002/pbc.21589](https://doi.org/10.1002/pbc.21589), PMID [18454466](https://pubmed.ncbi.nlm.nih.gov/18454466/).
8. Wajnrajch MP, et al. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. *Pediatrics.* 2001;107(4):744-754. View this article via: [PubMed CrossRef Google Scholar](https://pubmed.ncbi.nlm.nih.gov/11744744/)
9. Rietschel P, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. *J ClinEndocrinolMetab.* 2001;86(2):504-510. View this article via: [PubMed CrossRef Google Scholar](https://pubmed.ncbi.nlm.nih.gov/11744744/)
10. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconianemia: an International Fanconi Anemia Registry study. *Blood.* 1994;84(5):1650-1655. View this article via: [PubMed Google Scholar](https://pubmed.ncbi.nlm.nih.gov/7502512/)
11. Kutler DI, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). *Blood.* 2003;101(4):1249-1256. View this article via: [PubMed CrossRef Google Scholar](https://pubmed.ncbi.nlm.nih.gov/12491256/)
12. Quentin S, Cucchini W, Ceccaldi R, Nibourel O, Pondarre C, Pagès M, et al. Myelodysplasia and leukemia of Fanconianemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. *Blood.* 2011;117(15):e161-70. doi: [10.1182/blood-2010-09-308726](https://doi.org/10.1182/blood-2010-09-308726).
13. Meyer S, et al. Fanconianemia (FA)-associated 3q gains in leukemic transformation consistently target EVI1, but do not affect low TERC expression in FA. *Blood.* 2011;117(22):6047-6050. View this article via: [PubMed CrossRef Google Scholar](https://pubmed.ncbi.nlm.nih.gov/21490908/)
14. Meyer S, et al. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconianemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption. *Genes Chromosomes Cancer.* 2007;46(4):359-372. View this article via: [PubMed CrossRef Google Scholar](https://pubmed.ncbi.nlm.nih.gov/17490908/)
15. Du W, Adam Z, Rani R, Zhang X, Pang Q. Oxidative stress in Fanconianemia hematopoiesis and disease progression. *Antioxid Redox Signal.* 2008;10(11):1909-1921. View this article via: [PubMed CrossRef Google Scholar](https://pubmed.ncbi.nlm.nih.gov/18454466/)